Islet Cell Transplant Safety Study for Hard-to-Control Type 1 Diabetes
Tests islet cell transplants from donors in adults with hard-to-control type 1 diabetes.
Key facts
- Who runs it
- University of Chicago
- Where
- Chicago, United StatesSee the site
- Trial code
- Registry title
- Islet Transplantation in Patients With "Brittle" Type I Diabetes
- Status
- Recruiting
- People taking part
- 20 people, planned
- Started
- May 2012
- Expected to end
- Jun 2030
- Type of study
- Interventional
- Treatments tested
- Allogenic islet cells (human, U. Chicago)
- Intraportal infusion of islet cells
- Record updated
- 9 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-standing type 1 diabetes and severe low blood sugar episodes or very unstable blood sugar, to test the safety of islet cell transplantation.
- Age
- 18 to 70 years
- Sex
- Men and women
- Disease stage
- Type 1 diabetes that began before age 40, with insulin use for 5 years or more. Needs severe low blood sugar episodes or unstable blood sugar despite intensive diabetes care.
- Earlier treatment
- Must be on intensive diabetes care under a diabetes specialist. This means checking glucose at least 3 times a day and 3 or more insulin injections a day or an insulin pump.
- Biomarker or test result
- Absent stimulated c-peptide (<0.3ng/mL) in a mixed meal test, or reduced awareness of low blood sugar by Clarke or HYPO score, or marked glucose swings by LI score.
Main reasons for not taking part
- BMI >30 kg/m2 or weight <50kg (110 lb)
- Insulin need >1.0 IU/kg/day or <15 U/day
- Untreated proliferative diabetic retinopathy
- Active infection such as hepatitis B, hepatitis C, HIV or tuberculosis
- Pregnancy, breast-feeding, or wish to become pregnant
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Male and female patients 18 to 70 years of age
- Subjects who are able to provide written informed consent and to comply with the procedures of the study protocol
- Clinical history compatible with T1D with onset of disease at < 40 years of age, insulin-dependence for ≥ 5 years at the time of enrollment, and a sum of patient age and insulin dependent diabetes duration of ≥ 28 and absent stimulated c-peptide (<0.3ng/mL) in response to a mixed meal tolerance test (MMTT; Boost® 6 mL/kg body weight to a maximum of 360 mL; another product with equivalent caloric and nutrient content may be substituted for Boost) measured at 60 and 90 min after the start of consumption and at least one episode of severe hypoglycemia in the 12 months prior to study enrollment; OR a clinical history of "problematic hypoglycemia" defined as defined as two or more episodes per year of severe hypoglycemia or as one episode associated with impaired awareness of hypoglycemia, extreme glycemic lability, or major fear and maladaptive behavior according to recent clinical recommendations
- Involvement in intensive diabetes management defined as self monitoring of glucose values no less than a mean of three times each day averaged over each week and by the administration of three or more insulin injections each day or insulin pump therapy. Such management must be under the direction of an endocrinologist, diabetologist, or diabetes specialist with at least 3 clinical evaluations during the 12 months prior to study enrollment
- Reduced awareness of hypoglycemia as defined by a Clarke score of 4 or more OR a HYPO score greater than or equal to the 90th percentile (1047) during the screening period and within the last 6 months; OR marked glycemic lability characterized by wide swings in blood glucose despite optimal diabetes therapy and defined by an LI score greater than or equal to the 90th percentile (433 mmol/L2/h -wk1) during the screening period and within the last 6 months prior to randomization; OR a composite of a Clarke score of 4 or more and a HYPO score greater than or equal to the 75th percentile (423) and a LI greater than or equal to the 75th percentile (329) during the screening period and within the last 6 months
Who cannot take part
- Presence or history of panel-reactive anti-HLA antibodies above 30% or history/presence of donor specific anti-HLA antibodies in order to avoid unacceptable antigen(s) (Campbell PM 2007)
- Severe co-existing cardiac disease
- Measured glomerular filtration rate <80 mL/min/1.73m2 (using iohexol or calculated using the subject's measured serum creatinine and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI equation) or based on 24-hrs urine collection. Strict vegetarians (vegans) with a calculated GFR <70 mL/min/1.73m2 are excluded. The absolute (raw) GFR value will be used for subjects with body surface areas >1.73 m2
- Presence or history of macroalbuminuria (>300 mg/g creatinine)
- Presence or history of active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Subjects with laboratory evidence of active infection are excluded even in the absence of clinical evidence of active infection
- Body mass index (BMI) >30 kg/m2 or patient weight <50kg
- Insulin requirement >1.0 IU/kg/day or <15 U/day
- Untreated proliferative diabetic retinopathy
- Blood Pressure: SBP >160 mmHg or DBP >100 mmHg
- For female subjects: Positive pregnancy test, presently breast-feeding, wishes to be pregnant at any time point in the future, which includes during or after the completion of the study even if study participation is ended early, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable
- Known active alcohol or substance abuse
- Known hypercoagulative state
- Symptomatic cholecystolithiasis
- Acute or chronic pancreatitis; Other protocol related inclusion/exclusion criteria may apply
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- University of Chicago Medical CenterChicago, United StatesContact: Lindsay Basto, RN, BSNTaking people
About the trial
What the trial wants to find out
The purpose of this study is to learn about the safety of islet transplantation for Type 1 diabetes mellitus, which may provide more normal control of blood sugar without the need for insulin shots. Islets are special clusters of cells within the pancreas that produce insulin. These cells will be obtained from cadaver (non-living) donors and given to subjects by vein.
The group in the trial
- Allogenic islet cells (human, U. Chicago)Treatment being tested
Treatment: Allogenic islet cells (human, U. Chicago) and Intraportal infusion of islet cells
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Islet Transplantation in Patients With "Brittle" Type I Diabetes
- Plain-language title
- Islet Cell Transplant Safety Study for Hard-to-Control Type 1 DiabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT01630850, who can take part
- Record updated
- 9 December 2025